%0 Journal Article
%T Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ¡Ý 65 years) with inadequately controlled type 2 diabetes mellitus
%A Karyekar CS
%A Ravichandran S
%A Allen E
%A Fleming D
%J Clinical Interventions in Aging
%D 2013
%I Dove Medical Press
%X Chetan S Karyekar, Shoba Ravichandran, Elsie Allen, Douglas Fleming, Robert Frederich Bristol-Myers Squibb, Princeton, NJ, USA Purpose: To assess safety and efficacy of saxagliptin in older patients with type 2 diabetes mellitus (T2DM). Patients and methods: This was a post hoc analysis of pooled data from older patients (¡Ý65 years of age) from five 24-week phase III trials: three studies of saxagliptin versus placebo as an add-on therapy to metformin, glyburide, or a thiazolidinedione; and two studies of saxagliptin versus placebo as monotherapy in drug-na ve patients. Separate analyses were conducted on one study of initial combination therapy with saxagliptin plus metformin versus metformin monotherapy in drug-na ve patients. The safety analysis population for the five-study pool included 428 patients ¡Ý 65 years of age with baseline glycated hemoglobin (HbA1c) 7.0% to 10.5% who received saxagliptin 2.5 or 5 mg or placebo, and for the study of initial combination therapy included 69 patients ¡Ý 65 years of age with baseline HbA1c 8.0% to 12.0% who received saxagliptin 5 mg in combination with metformin or metformin monotherapy. The primary efficacy endpoint was change from baseline HbA1c. Results: In the five-study pool, the differences in the adjusted mean change from baseline HbA1c among older patients receiving saxagliptin versus placebo were -0.60% (95% confidence interval [CI], -0.99% to -0.21%) for saxagliptin 2.5 mg and -0.55% (-0.97% to -0.14%) for saxagliptin 5 mg; in the initial combination study, the difference was -1.22% (-2.27% to -0.17%) among older patients receiving saxagliptin 5 mg plus metformin versus metformin monotherapy. The results were generally similar in older and younger patients. Saxagliptin was well tolerated; the incidence and types of adverse events were similar for saxagliptin and comparators. Hypoglycemia was reported in 3.0% to 9.4% of patients receiving saxagliptin (0%¨C8.0% for comparators) and was confirmed (finger stick glucose ¡Ü 50 mg/dL, with associated symptoms) in 0% to 0.7% (0%¨C0.7% for comparators); hypoglycemic episodes did not vary by age category and did not require medical intervention. Conclusion: Saxagliptin was effective and well tolerated, with a low risk of hypoglycemia, when used as monotherapy, add-on therapy, or initial combination therapy with metformin in older patients with T2DM. Keywords: clinical trial, dipeptidyl peptidase-4, DPP-4 inhibitor, hypoglycemia, metformin
%U http://www.dovepress.com/tolerability-and-efficacy-of-glycemic-control-with-saxagliptin-in-olde-a12777